Clofarabine ± Fludarabine with Once Daily i.v. Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 6, 2011, Pages 893-900

  Andersson, Borje S ^a   Valdez, Benigno C ^a   de Lima, Marcos ^a   Wang, Xuemei ^a   Thall, Peter F ^a   Worth, Laura L ^a   Popat, Uday ^a   Madden, Timothy ^a   Hosing, Chitra ^a   Alousi, Amin ^a   Rondon, Gabriela ^a   Kebriaei, Partow ^a   Shpall, Elizabeth J ^a   Jones, Roy B ^a   Champlin, Richard E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Allogeneic; AML; Clofarabine; CML; Fludarabine; IV Busulfan; MDS; Stem Cell Transplantation

Indexed keywords

BUSULFAN; CLOFARABINE; FLUDARABINE; FLUDARABINE PHOSPHATE; METHOTREXATE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CHRONIC MYELOID LEUKEMIA; CYTOTOXICITY; DRUG POTENTIATION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; RANDOMIZED CONTROLLED TRIAL;

ADENINE NUCLEOTIDES; ANIMALS; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; BUSULFAN; CELL LINE, TUMOR; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; RABBITS; REMISSION INDUCTION; SURVIVAL ANALYSIS; TACROLIMUS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 79956017109     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.09.022     Document Type: Article

References (44)

1. Devergie A., Blaise D., Attal M., et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood 1995, 85:2263-2268.
2. Blume K.G., Kopecky K.J., Henslee-Downey J.P., et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. Blood 1993, 81:2187-2193.
3. Hartman A.R., Williams S., Dillon J.J. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant 1998, 22:439-443.
4. Socie G., Clift R.A., Blaise D., et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001, 98:3569-3574.
5. Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002, 8:468-477.
6. Russell J.A., Savoie M.L., Balogh A., et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 cGy total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant 2007, 13:814-821.
7. De Lima M., Couriel, Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004, 104:857-864.
8. Andersson B.S., de Lima M., Thall P.F., et al. Once daily IV busulfan and fludarabine compares favorably with IV busulfan and cyclophosphamide (IV BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008, 14:672-684.
9. Chae Y.S., Sohn S.K., Kim J.G., et al. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. Bone Marrow Transplant 2007, 40:541-547.
10. Bredeson C.N., Zhang M.J., Agovi M.A., et al. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:993-1003.
11. Kashyap A., Wingard J., Cagnoni P., et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002, 8:493-500.
12. Kim S.E., Lee J.H., Choi S.J., Lee J.H., Ryu S.G., Lee K.H. Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide: a retrospective comparison of oral versus intravenous busulfan. Haematologica 2005, 90:285-286.
13. Lee J.H., Choi S.J., Lee J.H., et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 2005, 84:321-330.
14. Madden T., de Lima M., Thapar N., et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant 2007, 13:56-64.
15. Vey N., De Prijck B., Faucher C., et al. A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refractory or relapsed hematological malignancies. Bone Marrow Transplant 1996, 18:495-499.
16. Matsuyama T., Kojima S., Kato K. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen. Bone Marrow Transplant 1998, 22:21-26.
17. Small T.N., Young J.W., Castro-Malaspina H., et al. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. Biol Blood Marrow Transplant 2007, 13:235-244.
18. Przepiorka D., Khouri I., Thall P., et al. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Bone Marrow Transplant 1999, 23:977-981.
19. Shimoni A., Hardan I., Shem-Tov N., et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006, 20:322-328.
20. Shimoni A., Hardan I., Shem-Tov N., Yerushalmi R., Nagler A. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity: long-term follow-up. Leukemia 2010, 24:1050-1052.
21. Wong R., Shahjahan M., Wang X., et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 2005, 11:108-114.
22. de Lima M., Anagnostopoulos A., Munsell M., et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004, 104:865-872.
23. Faderl S., Gandhi V., Keating M., et al. The role of clofarabine in hematologic and solid malignancies-development of a next-generation nucleoside analog. Cancer 2005, 103:1985-1995.
24. Faderl S., Ferrajoli A., Wierda W., et al. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 2008, 113:2090-2096.
25. Kantarjian H., Gandhi V., Kozuch P., et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003, 21:1167-1173.
26. Kantarjian H.M., Jeha S., Gandhi V., Wess M., Faderl S. Clofarabine: past, present and future. Leuk Lymphoma 2007, 48:1922-1930.
27. Kantarjian H., Erba H.P., Claxton D., et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010, 28:549-555.
28. Jeha S., Razzouk B., Rytting M., et al. Phase II study of clofarabine in pediatric patiens with refractory or relapsed acute myeloid leukemia. J Clin Oncol 2010, 27:4392-4397.
29. Valdez B.C., Murray D., Ramdas L., et al. Altered gene expression in busulfan-resistant human myeloid leukemia. Leuk Res 2008, 32:1684-1697.
30. Valdez B., Andersson B.S. Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies. Environ Mol Mutagenesis 2010, 51:659-668.
31. Terenzi A., Aristei C., Aversa F., et al. Efficacy of fludarabine as an immunosuppressor for bone marrow transplantation conditioning: preliminary results. Transplant Proc 1996, 28:3101.
32. Thall P.F., Wathen J.K. Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatments. Stat Med 2005, 24:1947-1964.
33. Thall P.F., Inoue L.Y.T., Martin T. Adaptive decision making in a lymphocyte infusion trial. Biometrics 2002, 58:560-568.
34. Thompson W.R. On the likelihood that one unknown probability exceeds another in view of the evidence of two samples. Biometrika 1933, 25:285-294.
35. Andersson B.S., Bergerheim U.S.R., Collins V.P., et al. KBM-3, an in vitro model of human acute myelomonocytic leukemia. Exp Hematol 1992, 20:361-367.
36. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
37. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
38. Przepiorka D., Khouri I., Ippoliti C., et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant 1999, 24:763-768.
39. Keating M.J., Smith T.L., Gehan E.A., et al. Factors related to length of complete remission in adult acute leukemia. Cancer 1980, 45:2017-2029.
40. Greenberg P., Cox C., LeBeau M.M., et al. International Scoring System for evaluateing prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
41. Common Terminology Criteria v3.0. NIH Publication No. 03-5410, June 2003.
42. Yamauchi T., Nowak B.J., Keating M.J., Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001, 7:3580-3589.
43. Bibawi S., Abi-Said D., Fayad L., et al. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol 2001, 67:227-233.
44. Andersson B.S., Thall P.F., Madden T., et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002, 8:477-485.